NewsONCOLOGY AND THERAPYWednesday, April 1, 2026 · April 1, 2026
Results from a Pilot Study of HyBryte™ (Topical Synthetic Hypericin) Versus Valchlor ® (Mechlorethamine) in the Treatment of CTCL.
WHY IT MATTERS
Recent peer-reviewed research on Primary cutaneous T-cell lymphoma that may be relevant for patients and caregivers.
Mycosis fungoides (MF) is the most common type of primary cutaneous T-cell lymphoma (CTCL), a malignant and chronic skin disease. Early-stage MF has a generally favorable prognosis, but effective and well-tolerated skin-directed therapies are crucial for management. HyBryte™ is a photodynamic...
Related conditions
Related news
Int J Circumpolar Health · -249 days ago
A population-based legacy study of myasthenia gravis in Iceland: insights from a small Arctic nation
Published in Int J Circumpolar Health. Hjaltason H et al.…
Ther Adv Rare Dis · -219 days ago
Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy
Published in Ther Adv Rare Dis. Mitha A et al.…
Health Inf Sci Syst · -219 days ago
PhenoRareAI: Phenotype-based intelligent diagnosis for rare neuromuscular disorders of glycogen storage disease and spinal muscular atrophy
Published in Health Inf Sci Syst. Zhai W et al.…
Mol Ther Nucleic Acids · -51 days ago
The post-pandemic pivot: mRNA therapeutics enter the chronic rare disease arena
Published in Mol Ther Nucleic Acids. Giangrande PH et al.…